Covered recipient · General Payments record
WILLIAM HONEYCUTT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$23,501.87
195 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,887.00 | 5 |
| Food and Beverage | $3,329.33 | 186 |
| Travel and Lodging | $1,285.54 | 4 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech USA, Inc. | $8,846.96 | 22 |
| GENZYME CORPORATION | $7,433.10 | 9 |
| EMD Serono, Inc. | $4,752.38 | 7 |
| ABBVIE INC. | $591.13 | 45 |
| PFIZER INC. | $274.84 | 13 |
| Novartis Pharmaceuticals Corporation | $246.77 | 44 |
| Lundbeck LLC | $155.66 | 6 |
| Genentech, Inc. | $121.53 | 1 |
| Eisai Inc. | $120.70 | 3 |
| Lilly USA, LLC | $84.14 | 5 |
| Otsuka America Pharmaceutical, Inc. | $76.08 | 3 |
| Teva Pharmaceuticals USA, Inc. | $75.36 | 3 |
| Amgen Inc. | $69.09 | 3 |
| Biogen, Inc. | $61.57 | 3 |
| Neurelis, Inc. | $56.94 | 3 |
| Neurocrine Biosciences, Inc. | $56.45 | 3 |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $56.07 | 3 |
| Avadel CNS Pharmaceuticals, LLC | $55.08 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $50.51 | 2 |
| Celgene Corporation | $50.06 | 2 |
| CATALYST PHARMACEUTICALS, INC. | $44.47 | 2 |
| GE HEALTHCARE | $40.65 | 2 |
| Sumitomo Pharma America, Inc. | $39.81 | 2 |
| SCILEX PHARMACEUTICALS INC. | $39.55 | 2 |
| Averitas Pharma Inc. | $28.76 | 1 |
| Vanda Pharmaceuticals Inc. | $20.34 | 1 |
| LivaNova USA, Inc. | $20.09 | 1 |
| Alexion Pharmaceuticals, Inc. | $17.22 | 1 |
| ARGENX US, INC. | $16.56 | 1 |
Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM HONEYCUTT
NPI 1457340960 · CMS profile ID 247917
MAITLAND, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457340960?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457340960?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457340960?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- WILLIAM HONEYCUTT, NPI 1457340960, CMS profile ID 247917, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457340960?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
195 matching records · $23,501.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 195.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $4.65 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134030 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $20.44 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144508850 | CMS |
| Novartis Pharmaceuticals Corporation | $1.12 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783599 | CMS |
| Novartis Pharmaceuticals Corporation | $2.74 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783607 | CMS |
| ABBVIE INC. | $10.08 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935497 | CMS |
| Novartis Pharmaceuticals Corporation | $16.86 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783593 | CMS |
| ABBVIE INC. | $21.69 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935495 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.92 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137578744 | CMS |
| Novartis Pharmaceuticals Corporation | $2.62 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783597 | CMS |
| Novartis Pharmaceuticals Corporation | $1.18 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783605 | CMS |
| PFIZER INC. | $21.99 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131490643 | CMS |
| ABBVIE INC. | $7.78 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935493 | CMS |
| Genentech USA, Inc. | $5.85 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134026 | CMS |
| Novartis Pharmaceuticals Corporation | $1.86 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783587 | CMS |
| PFIZER INC. | $19.73 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131495502 | CMS |
| Biogen, Inc. | $15.74 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104876270 | CMS |
| GENZYME CORPORATION | $96.34 | 04/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139608718 | CMS |
| ABBVIE INC. | $4.50 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935491 | CMS |
| Genentech USA, Inc. | $48.85 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134054 | CMS |
| Genentech USA, Inc. | $2,830.00 | 04/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134058 | CMS |
| Novartis Pharmaceuticals Corporation | $17.80 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783589 | CMS |
| Novartis Pharmaceuticals Corporation | $3.50 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783591 | CMS |
| PFIZER INC. | $27.88 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131482416 | CMS |
| ABBVIE INC. | $5.79 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935489 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.22 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533150 | CMS |
| ABBVIE INC. | $28.67 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935487 | CMS |
| EMD Serono, Inc. | $24.29 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120220337 | CMS |
| Genentech USA, Inc. | $193.83 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134002 | CMS |
| Genentech USA, Inc. | $781.62 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134006 | CMS |
| Genentech USA, Inc. | $133.24 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134010 | CMS |
| Genentech USA, Inc. | $4,520.00 | 04/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134014 | CMS |
| Genentech USA, Inc. | $59.17 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134018 | CMS |
| Novartis Pharmaceuticals Corporation | $2.80 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783569 | CMS |
| Novartis Pharmaceuticals Corporation | $2.16 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783571 | CMS |
| Eisai Inc. | $22.65 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110788907 | CMS |
| Genentech USA, Inc. | $99.51 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134022 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $18.42 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144446124 | CMS |
| GENZYME CORPORATION | $27.52 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139608712 | CMS |
| ABBVIE INC. | $18.83 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935485 | CMS |
| GE HEALTHCARE | $14.39 | 03/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144683372 | CMS |
| Novartis Pharmaceuticals Corporation | $3.00 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783567 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.76 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118909903 | CMS |
| ABBVIE INC. | $6.14 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935483 | CMS |
| Lundbeck LLC | $17.33 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145926044 | CMS |
| Genentech USA, Inc. | $4.84 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133133998 | CMS |
| GENZYME CORPORATION | $31.23 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139608746 | CMS |
| GENZYME CORPORATION | $3,537.00 | 03/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139608748 | CMS |
| SCILEX PHARMACEUTICALS INC. | $19.58 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136231341 | CMS |
| Genentech, Inc. | $121.53 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133134062 | CMS |
| ABBVIE INC. | $19.32 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103935481 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $33,383.15 | 2 |
| PY2025 | Principal investigator | $2,710,878.47 | 158 |
| PY2024 | Recipient | $1,168.37 | 2 |
| PY2024 | Principal investigator | $2,343,096.29 | 131 |
| PY2023 | Principal investigator | $2,705,246.13 | 84 |
| PY2022 | Principal investigator | $1,952,482.19 | 53 |
| PY2021 | Recipient | $100.00 | 1 |
| PY2021 | Principal investigator | $1,534,845.61 | 72 |
| PY2020 | Recipient | $17,817.51 | 2 |
| PY2020 | Principal investigator | $1,295,151.46 | 65 |
| PY2019 | Recipient | $136,923.47 | 19 |
| PY2019 | Principal investigator | $1,035,814.44 | 109 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
160 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $201.00 | 12/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES, PA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis | No dispute reported | 06/30/2026 | 1190313927 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627528 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627531 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627537 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627540 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627545 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627552 |
| Principal investigator 1 | Genentech, Inc. | $4,186.00 | 12/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627683 |
| Principal investigator 1 | Genentech, Inc. | $8,226.00 | 12/16/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) | No dispute reported | 06/30/2026 | 1211627580 |
| Recipient | Hexal AG | $12,892.64 | 12/09/2025 | Covered Recipient Physician | CCYB704A12301 | No dispute reported | 06/30/2026 | 1186348484 |
| Principal investigator 1 | Genentech, Inc. | $11,081.00 | 12/04/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211627643 |
| Principal investigator 1 | GENZYME CORPORATION | $9,702.00 | 12/02/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136135 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $250.00 | 12/01/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627548 |
| Principal investigator 1 | Genentech, Inc. | $10,698.00 | 11/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | OCARINA 3 | No dispute reported | 06/30/2026 | 1211627575 |
| Principal investigator 1 | Genentech, Inc. | $2,093.00 | 11/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627678 |
| Principal investigator 1 | Genentech, Inc. | $1,383.00 | 11/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627640 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 11/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627521 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 11/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627524 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 11/19/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627534 |
| Principal investigator 1 | GENZYME CORPORATION | $5,823.90 | 11/17/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136125 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $250.00 | 11/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365871 |
| Principal investigator 1 | Genentech, Inc. | $5,335.00 | 11/05/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627670 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $250.00 | 11/05/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242365719 |
| Principal investigator 1 | GENZYME CORPORATION | $57,120.00 | 11/04/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136122 |
| Principal investigator 1 | Genentech, Inc. | $9,995.00 | 10/29/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) | No dispute reported | 06/30/2026 | 1211627567 |
| Principal investigator 1 | Genentech, Inc. | $1,020.00 | 10/28/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | OCARINA 3 | No dispute reported | 06/30/2026 | 1211627571 |
| Principal investigator 1 | Genentech, Inc. | $5,367.00 | 10/28/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627636 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $684.00 | 10/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627502 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 10/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627506 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 10/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627511 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 10/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627514 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 10/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627518 |
| Principal investigator 1 | GENZYME CORPORATION | $5,888.30 | 10/20/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | No dispute reported | 06/30/2026 | 1226136116 |
| Principal investigator 1 | Genentech, Inc. | $2,366.00 | 10/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627674 |
| Principal investigator 1 | ABBVIE INC. | $9,500.00 | 10/14/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202516753 |
| Principal investigator 1 | ABBVIE INC. | $5,066.96 | 10/14/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202516755 |
| Recipient | Hexal AG | $20,490.51 | 10/14/2025 | Covered Recipient Physician | CCYB704A12301 | No dispute reported | 06/30/2026 | 1186348486 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,065.00 | 10/02/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359870 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,186.00 | 10/02/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242359872 |
| Principal investigator 1 | GENZYME CORPORATION | $4,428.45 | 09/29/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136090 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627411 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627425 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627456 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627459 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627478 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,430.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627482 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627486 |
| Principal investigator 1 | Genentech, Inc. | $62,644.00 | 09/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211627618 |
| Principal investigator 1 | Genentech, Inc. | $55,345.00 | 09/18/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627667 |
| Principal investigator 1 | Genentech, Inc. | $4,732.00 | 09/17/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627663 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,750.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627428 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $250.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627442 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627450 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,500.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627474 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627490 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,585.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627496 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,500.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358840 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8,793.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358842 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,032.00 | 09/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358844 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,065.00 | 09/08/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242358700 |
| Principal investigator 1 | GENZYME CORPORATION | $9,944.80 | 09/03/2025 | Non-covered Recipient Entity Neurology Associates, Pa | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136070 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,269.22 | 09/01/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190305885 |
| Principal investigator 1 | Genentech, Inc. | $11,377.00 | 08/27/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | OCARINA 3 | No dispute reported | 06/30/2026 | 1211627558 |
| Principal investigator 1 | Genentech, Inc. | $97,630.00 | 08/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627627 |
| Principal investigator 1 | Genentech, Inc. | $2,758.00 | 08/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211627631 |
| Principal investigator 1 | Genentech, Inc. | $14,832.00 | 08/15/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211627623 |
| Principal investigator 1 | Genentech, Inc. | $6,720.00 | 08/13/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | OCARINA 3 | No dispute reported | 06/30/2026 | 1211627563 |
| Principal investigator 1 | GENZYME CORPORATION | $77,492.00 | 08/11/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136059 |
| Principal investigator 1 | ABBVIE INC. | $8,250.00 | 08/06/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202503609 |
| Principal investigator 1 | GENZYME CORPORATION | $1,750.50 | 08/04/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136040 |
| Principal investigator 1 | GENZYME CORPORATION | $3,600.00 | 08/04/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136043 |
| Principal investigator 1 | GENZYME CORPORATION | $1,750.50 | 08/04/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136048 |
| Principal investigator 1 | GENZYME CORPORATION | $7,750.80 | 07/28/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136052 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627398 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627403 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627408 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627414 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627418 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627421 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627431 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,570.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627434 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627439 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627446 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627453 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627465 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 07/23/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627469 |
| Principal investigator 1 | GENZYME CORPORATION | $11,522.90 | 07/21/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136300 |
| Principal investigator 1 | GENZYME CORPORATION | $56,762.30 | 07/21/2025 | Non-covered Recipient Entity Neurology Associates, Pa | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136302 |
| Principal investigator 1 | Genentech, Inc. | $5,367.00 | 07/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627614 |
| Principal investigator 1 | Genentech, Inc. | $6,279.00 | 07/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627658 |
| Principal investigator 1 | GENZYME CORPORATION | $5,888.30 | 07/14/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | No dispute reported | 06/30/2026 | 1226136318 |
| Principal investigator 1 | GENZYME CORPORATION | $4,073.40 | 07/02/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136295 |
| Principal investigator 1 | GENZYME CORPORATION | $5,694.70 | 07/02/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | No dispute reported | 06/30/2026 | 1226136322 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 06/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627363 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 06/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627368 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 06/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627381 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 06/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627395 |
| Principal investigator 1 | Hexal AG | $11,211.75 | 06/17/2025 | Non-covered Recipient Entity Neurology Associates P.A. | CCYB704A12301 | No dispute reported | 06/30/2026 | 1186348910 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $721.00 | 06/04/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242348822 |
| Principal investigator 1 | Genentech, Inc. | $20,260.00 | 06/03/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211627585 |
| Principal investigator 1 | Genentech, Inc. | $2,366.00 | 05/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627649 |
| Principal investigator 1 | GENZYME CORPORATION | $2,762.40 | 05/19/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136272 |
| Principal investigator 1 | Genentech, Inc. | $21,966.60 | 05/14/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211627605 |
| Principal investigator 1 | Genentech, Inc. | $49,481.00 | 05/13/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | OCARINA 3 | No dispute reported | 06/30/2026 | 1211627555 |
| Principal investigator 1 | Genentech, Inc. | $5,367.00 | 05/09/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627601 |
| Principal investigator 1 | Genentech, Inc. | $4,137.00 | 05/02/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211627611 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 04/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627372 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 04/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627378 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 04/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627384 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 04/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627387 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 04/25/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627391 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,000.00 | 04/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190299968 |
| Principal investigator 1 | GENZYME CORPORATION | $5,276.25 | 04/14/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136241 |
| Principal investigator 1 | GENZYME CORPORATION | $858.40 | 04/07/2025 | Non-covered Recipient Entity Neurology Associates, Pa | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136184 |
| Principal investigator 1 | Genentech, Inc. | $14,349.00 | 04/02/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211627654 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $241,389.56 | 03/31/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190305893 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627294 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,594.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627301 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627314 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627318 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627330 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,624.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627333 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627336 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,788.00 | 03/21/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627347 |
| Principal investigator 1 | GENZYME CORPORATION | $6,906.00 | 03/17/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136175 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,065.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334718 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,186.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334720 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,497.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334722 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,382.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334724 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $721.00 | 03/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242334730 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $357,514.40 | 03/05/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse | No dispute reported | 06/30/2026 | 1190305889 |
| Principal investigator 1 | GENZYME CORPORATION | $1,921.70 | 03/04/2025 | Non-covered Recipient Entity Neurology Associates, Pa | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | No dispute reported | 06/30/2026 | 1226136171 |
| Principal investigator 1 | ABBVIE INC. | $2,343.51 | 02/27/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | No dispute reported | 06/30/2026 | 1202455049 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,271.76 | 02/27/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES | A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy | No dispute reported | 06/30/2026 | 1190299960 |
| Principal investigator 1 | GENZYME CORPORATION | $8,060.50 | 02/24/2025 | Non-covered Recipient Entity Neurology Associates, Pa | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136180 |
| Principal investigator 1 | Genentech, Inc. | $32,934.00 | 02/20/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211627593 |
| Principal investigator 1 | Genentech, Inc. | $403.00 | 02/14/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211627589 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,065.00 | 02/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330279 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,186.00 | 02/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330281 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,295.00 | 02/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330283 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,895.00 | 02/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330285 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,697.00 | 02/07/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | ITI-214-202 | No dispute reported | 06/30/2026 | 1242330287 |
| Principal investigator 1 | Genentech, Inc. | $10,250.00 | 02/04/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211627596 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,499.14 | 01/28/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190299956 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,067.00 | 01/28/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190299964 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $379,115.75 | 01/27/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES, PA | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190304187 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,624.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627305 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627311 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,624.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627322 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,624.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627326 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627339 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627343 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $5,624.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627350 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627355 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $223.00 | 01/22/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211627360 |
| Principal investigator 1 | ABBVIE INC. | $5,656.51 | 01/16/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202439817 |
| Principal investigator 1 | GENZYME CORPORATION | $4,073.40 | 01/13/2025 | Non-covered Recipient Entity Neurology Associates, Pa | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226136200 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $79,184.06 | 01/06/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES PA | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190305891 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,554.00 | 01/01/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES, PA | A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy | No dispute reported | 06/30/2026 | 1190304189 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $564,218.75 | 01/01/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES, PA | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190304191 |